Covid 19 Therapeutics – Review of Active Pharmaceutical Ingredients (APIs)

Boulder BioScience has developed an API candidate for Covid 19 treatment. The mechanism of action for the API includes non-toxic kinase inhibition providing a treatment response for pulmonary viral infection. This introduces a new approach to reducing viral load, controlling unwanted immune driven inflammation, and preventing lung and other organ damage. The orally administered API modulates excessive and tissue destructive antiviral defenses against pulmonary viral infection, providing for successful resolution of Covid 19 through limiting overactive innate immunity.

Comparison of Anti-Covid 19 Related Activity from Available APIs

Anti-Covid 19 Activity Boulder BioScience API* Repurposed Partner Drug Approved or in Development for Covid 19

Remdecivir Anti-viral

EIDD-2801 Anti-viral

Ibrutanib BTK inbibitor

Acalabrutinib BTK inbibitor

Eculizumab Anti-C5

Anakinra Anti-IL-1R
Viral Load Reduction Yes* Yes Yes No No No No
Reduce Lung Inflammation Yes* No No Yes Yes Yes Yes
Organ Protection Yes* No No Yes Yes Yes Yes
Anti-Thrombosis Yes No No No No No No
Neutrophil Inhibition Yes* No No Yes Yes No No
Platelet Inhibition Yes No No No No No No
Cytokine Inhibition Yes No No Yes Yes No Yes
Complement Inhibition No No No No No Yes No
Route of Administration Oral IV Oral Oral Oral SubQ Oral

Boulder BioScience API* vs. Remdecivir Anti-viral

Anti-Covid 19 Activity Boulder BioScience API* Remdecivir Anti-viral
Viral Load Reduction Yes* Yes
Reduce Lung Inflammation Yes* No
Organ Protection Yes* No
Anti-Thrombosis Yes No
Neutrophil Inhibition Yes* No
Platelet Inhibition Yes No
Cytokine Inhibition Yes No
Complement Inhibition No No
Route of Administration Oral IV

Boulder BioScience API* vs. EIDD-2801 Anti-viral

Anti-Covid 19 Activity Boulder BioScience API* EIDD-2801 Anti-viral
Viral Load Reduction Yes* Yes
Reduce Lung Inflammation Yes* No
Organ Protection Yes* No
Anti-Thrombosis Yes No
Neutrophil Inhibition Yes* No
Platelet Inhibition Yes No
Cytokine Inhibition Yes No
Complement Inhibition No No
Route of Administration Oral Oral

Boulder BioScience API* vs. Ibrutanib BTK inbibitor

Anti-Covid 19 Activity Boulder BioScience API* Ibrutanib BTK inbibitor
Viral Load Reduction Yes* No
Reduce Lung Inflammation Yes* Yes
Organ Protection Yes* Yes
Anti-Thrombosis Yes No
Neutrophil Inhibition Yes* Yes
Platelet Inhibition Yes No
Cytokine Inhibition Yes Yes
Complement Inhibition No No
Route of Administration Oral Oral

Boulder BioScience API* vs. Acalabrutinib BTK inbibitor

Anti-Covid 19 Activity Boulder BioScience API* Acalabrutinib BTK inbibitor
Viral Load Reduction Yes* No
Reduce Lung Inflammation Yes* Yes
Organ Protection Yes* Yes
Anti-Thrombosis Yes No
Neutrophil Inhibition Yes* Yes
Platelet Inhibition Yes No
Cytokine Inhibition Yes Yes
Complement Inhibition No No
Route of Administration Oral Oral

Boulder BioScience API* vs. Eculizumab Anti-C5

Anti-Covid 19 Activity Boulder BioScience API* Eculizumab Anti-C5
Viral Load Reduction Yes* No
Reduce Lung Inflammation Yes* Yes
Organ Protection Yes* Yes
Anti-Thrombosis Yes No
Neutrophil Inhibition Yes* No
Platelet Inhibition Yes No
Cytokine Inhibition Yes No
Complement Inhibition No Yes
Route of Administration Oral SubQ

Boulder BioScience API* vs. Anakinra Anti-IL-1R

Anti-Covid 19 Activity Boulder BioScience API* Anakinra Anti-IL-1R
Viral Load Reduction Yes* No
Reduce Lung Inflammation Yes* Yes
Organ Protection Yes* Yes
Anti-Thrombosis Yes No
Neutrophil Inhibition Yes* No
Platelet Inhibition Yes No
Cytokine Inhibition Yes Yes
Complement Inhibition No No
Route of Administration Oral Oral

Notes: * = Data on File, Boulder BioScience, LLC